A porous material for mediating recombination of heterogeneous biological macromolecules at an interface, a preparation method and applications thereof
By mediating the recombination of heterogeneous biomacromolecule interfaces through small molecules, the problems of local aggregation and interfacial discontinuity during the composite of heterogeneous biomacromolecules are solved, forming a porous material with interconnected channels. This material has rapid hemostasis, antibacterial properties, and high biocompatibility, making it suitable for hemostatic materials.
Patent Information
- Application Number
- CN202611387890.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-08
- Publication Date
- 2026-11-13
AI Technical Summary
In existing technologies, when multiple heterogeneous biomacromolecules are directly compounded, local aggregation, interface discontinuity, and random structural organization are prone to occur, resulting in insufficient structural retention of porous materials after liquid absorption.
A method for small molecule-mediated heterogeneous biomacromolecule interface recombination is adopted, in which at least two biomacromolecules are mixed with a small molecule interface mediator to form a continuous recombinant heterogeneous interface through non-covalent interactions, and then dried and fixed to form a hierarchical porous network with interconnected channels.
It improves the continuity of heterogeneous biomacromolecule interfaces, reduces the fracture area of pore walls, narrows the orientation angle distribution, and reduces orientation entropy, thereby enhancing the pore wall continuity and structural stability of porous materials. It also has rapid coagulation and hemostasis properties, high porosity, good biocompatibility, and antibacterial properties.
Smart Images

Figure CN123078698A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical porous materials technology, and more specifically, relates to a porous material, preparation method and application of which is mediated by small molecules to reorganize heterogeneous biological macromolecule interfaces. Background Technology
[0002] Natural biomacromolecules such as collagen, chitosan, chitin, dextran, and fungal mycelium possess excellent biocompatibility, liquid absorption capacity, or coagulation potential, and have been used in the construction of sponges, aerogels, dressings, and filling materials. However, biomacromolecules from different sources differ in chemical composition, molecular conformation, surface functional groups, rigidity / flexibility properties, and aggregation morphology. Direct compounding can easily lead to local aggregation, random entanglement, interfacial discontinuities, and pore wall defects. These interfacial mismatches reduce the structural continuity of porous materials and affect liquid transport, blood retention, and post-absorption morphology retention.
[0003] Existing technologies typically adjust pore structure by increasing component content, introducing covalent crosslinking agents, or using frozen templates. Increasing component content does not necessarily improve interfacial contact between heterogeneous components; while covalent crosslinking can enhance network stability, it may alter the conformation of natural biomacromolecules or introduce residual control issues; frozen templates mainly regulate macroscopic pore morphology and cannot replace the adaptation of heterogeneous interfaces before freezing.
[0004] Therefore, existing technologies have technical problems such as local aggregation, interface discontinuity, and random structural organization when multiple heterogeneous biomacromolecules are directly compounded, resulting in insufficient structural retention after liquid absorption when used as a hemostatic porous material. Summary of the Invention
[0005] In view of the above-mentioned defects or improvement needs of the existing technology, the present invention provides a porous material, preparation method and application of small molecule-mediated heterogeneous biomacromolecule interface recombination, which aims to solve the technical problems of local aggregation, interface discontinuity and random structure organization when multiple heterogeneous biomacromolecules are directly compounded.
[0006] According to a first aspect of the present invention, a method for preparing a porous material with small molecule-mediated heterogeneous biomacromolecule interface recombination is provided, comprising the following steps: (1) Mix at least two different biomacromolecules with a small molecule interface mediator to obtain a composite precursor; the small molecule interface mediator contains multiple action sites that can interact non-covalently with the at least two biomacromolecules respectively, so that the small molecule interface mediator interacts non-covalently with the biomacromolecules respectively to form a continuous recombinant heterogeneous interface. (2) After drying and structural fixation, the recombined heterogeneous interface forms a hierarchical porous network with interconnected channels, resulting in a porous material with small molecule-mediated heterogeneous biomacromolecule interface recombination.
[0007] Preferably, the non-covalent interaction is at least one of hydrogen bonding, polar interaction, electrostatic interaction, aromatic interaction, hydrophobic interaction, and van der Waals interaction.
[0008] Preferably, the biomacromolecule is selected from at least two of the following: protein biomacromolecules, polysaccharide biomacromolecules, proteoglycans, and fungal mycelia.
[0009] Preferably, the protein-based biomolecules are selected from collagen, gelatin, silk fibroin, fibroin, elastin, or keratin; the polysaccharide-based biomolecules are selected from chitosan, chitin, cellulose, alginate, hyaluronic acid, starch, dextran, pectin, or agarose; and the fungal mycelium is a fungal mycelium containing a chitin and / or dextran fiber network. Preferably, the fungal hyphae are selected from Ganoderma lucidum mycelium, oyster mushroom mycelium, shiitake mushroom mycelium, wood ear mushroom mycelium, lion's mane mushroom mycelium, enoki mushroom mycelium, or Turmeric corydalis mycelium.
[0010] Preferably, the small molecule interface mediator is selected from at least one of polyphenolic compounds, phenolic acid compounds, anthocyanin compounds, flavonoid compounds, and catechin compounds.
[0011] Preferably, the anthocyanin compounds are selected from grape skin anthocyanins, malvidin, petunia extract, paeoniflorin, delphinidin, or cyanidin. The phenolic acid compounds are selected from gallic acid, protocatechuic acid, caffeic acid, ferulic acid, or ellagic acid; The catechin compounds are selected from catechins, epicatechins, or epigallocatechins.
[0012] Preferably, the drying process is freeze-drying or supercritical drying.
[0013] According to another aspect of the present invention, a porous material prepared by small molecule-mediated heterogeneous biomacromolecule interface recombination is provided.
[0014] According to another aspect of the present invention, the porous material described above, which mediates the recombination of heterogeneous biomacromolecule interfaces, is provided for the preparation of hemostatic materials.
[0015] Preferably, the hemostatic material is a wound compression hemostatic material or a cavity filling hemostatic material.
[0016] In summary, compared with the prior art, the above-described technical solutions conceived by this invention mainly possess the following technical advantages: (1) This invention utilizes small molecules as non-covalent interface mediators for heterogeneous biomacromolecule interface recombination, and fixes the resulting recombined interface into a porous material with interconnected channels. Small molecule-mediated heterogeneous biomacromolecule interface recombination refers to the introduction of small molecule interface mediators containing multiple non-covalent interaction sites during the formation of heterogeneous contacts between at least two biomacromolecules with different chemical compositions, molecular conformations, surface functional groups, and / or aggregation forms. Small molecules can interact non-covalently with different biomacromolecules, thereby changing the number, position, continuity, and spatial distribution of the original interface contacts, transforming the original discrete, locally aggregated, or randomly entangled heterogeneous contacts into continuous recombined heterogeneous interfaces. Interface recombination does not require the formation of new covalent bonds, nor does it require the formation of long-range ordered structures in the crystallographic sense. It is characterized by improved uniformity of distribution of different biomacromolecules, improved continuity of interface contacts, reduced fracture regions of pore walls, reduced local aggregation, narrowed orientation angle distribution, reduced orientation entropy, increased Herman orientation factor, enhanced anisotropy of small-angle X-ray scattering, changes in the chemical environment of interface-related functional groups, and / or changes in surface potential. Small molecules with multi-site interaction capabilities are used to regulate the interfacial contact and spatial organization between heterogeneous biomacromolecules. The structure is then fixed by subsequent drying, and the heterogeneous interface is reorganized to form a hierarchical porous network with interconnected channels, resulting in a porous material with small molecule-mediated reorganization of heterogeneous biomacromolecule interfaces.
[0017] (2) The porous material of the present invention, which is a small molecule-mediated heterogeneous biomacromolecule interface recombination material, has rapid coagulation and hemostatic properties. Thanks to the "capillary pump" effect brought about by the directional layered porous structure, the porous material can instantly absorb excess water from the wound and rapidly accumulate platelets and coagulation factors. The coagulation index (BCI) after 30 seconds of contact with blood is as low as about 1.5%, which is better than single-component and binary-component materials, and achieves rapid closure of massive bleeding.
[0018] (3) The application of the porous material of the present invention, which is a hemostatic material mediated by small molecules to reorganize heterogeneous biological macromolecule interfaces, has blood compatibility and safety: the whole components of the present invention are derived from natural extracts, and the hemolysis rate is controlled between 1.1% and 1.5%, which ensures the safety of the material when in contact with circulating blood.
[0019] (4) The porous material of the present invention, which is mediated by small molecules to reorganize heterogeneous biological macromolecule interfaces, has a porosity of up to 90%-99%, and has good structural integrity and certain mechanical strength in a wet state. It can effectively maintain the pressure on the wound and is not easy to cause secondary damage when removed.
[0020] (5) Preferably, the small molecule interface mediator of the present invention is a polyphenol compound, a phenolic acid compound, anthocyanin compound, a flavonoid compound, or a catechin compound, which has antibacterial properties; furthermore, the anthocyanin small molecules produce a synergistic biological effect with mycelial polysaccharides, so that the aerogel has an antibacterial rate of more than 99% against Escherichia coli and Staphylococcus aureus. This provides a natural antibacterial microenvironment for damaged tissues, and can effectively prevent secondary infection of wounds without the need for additional antibiotics. Attached Figure Description
[0021] Figure 1 The images are scanning electron microscope (SEM) images of the natural macromolecular high-efficiency hemostatic aerogels prepared in Examples 1-3 and Comparative Examples 1-5.
[0022] Figure 2 The images are fluorescence confocal microscopy images of the natural macromolecular high-efficiency hemostatic aerogels prepared in Examples 1-3 and Comparative Examples 1-5.
[0023] Figure 3 The images show the mesoscale ordered characterization of the natural macromolecules prepared in Examples 1-3 and Comparative Examples 1-5. (a. Herman orientation factor, b. orientation entropy, c. SAXS characterization).
[0024] Figure 4 XPS characterization images of the elemental composition and chemical state of the surface of the natural macromolecular materials prepared in Example 1 and Comparative Examples 1-5.
[0025] Figure 5 XPS images of the natural macromolecular materials prepared in Examples 4 and 5.
[0026] Figure 6 The image shows the XPS plot of the natural macromolecular material prepared in Example 6.
[0027] Figure 7 The surface potential characterization diagrams are of the natural macromolecular composites prepared in Examples 1-3 and Comparative Examples 1-5.
[0028] Figure 8 Porosity diagrams of the natural macromolecular high-efficiency hemostatic aerogels prepared in Examples 1-3 and Comparative Examples 1-5.
[0029] Figure 9 The graph shows the Escherichia coli inhibition rate test results of the natural macromolecular high-efficiency hemostatic aerogels prepared in Examples 1-3 and Comparative Examples 1-5.
[0030] Figure 10 The graph shows the test results of the Staphylococcus aureus inhibition rate of the natural macromolecular high-efficiency hemostatic aerogels prepared in Examples 1-3 and Comparative Examples 1-5.
[0031] Figure 11 Scanning electron microscope images of the antibacterial effect of the natural macromolecular high-efficiency hemostatic aerogels prepared in Examples 1-3 and Comparative Examples 1-5 on Escherichia coli.
[0032] Figure 12 Scanning electron microscope (SEM) images of the antibacterial effect of the natural macromolecular high-efficiency hemostatic aerogels prepared in Examples 1-3 and Comparative Examples 1-5 on Staphylococcus aureus.
[0033] Figure 13 This is a visualization of the absorption process of the natural macromolecular high-efficiency hemostatic aerogels prepared in Examples 1-3 and Comparative Examples 1-5 after contact with blood.
[0034] Figure 14 The graphs show the hemolysis rate test results of the natural macromolecular high-efficiency hemostatic aerogels prepared in Examples 1-3 and Comparative Examples 1-5.
[0035] Figure 15 The images show the hemostasis effect of the natural macromolecular high-efficiency hemostatic aerogels prepared in Examples 1-3 and Comparative Examples 1-5 using the inverted tube method.
[0036] Figure 16 The graph shows the in vitro coagulation index determination results of the natural macromolecular high-efficiency hemostatic aerogels prepared in Examples 1-3 and Comparative Examples 1-5.
[0037] In the figure: C represents the pure collagen aerogel in Comparative Example 1; CpA represents the composite aerogel of collagen with grape skin anthocyanins in Comparative Example 4; CM represents the composite aerogel of collagen with Ganoderma lucidum mycelium in Comparative Example 3; CMpA2-CMpA5 represent the composite aerogels of pure collagen with grape skin anthocyanins and Ganoderma lucidum mycelium in the three examples. Specifically, CMpA4 is the natural macromolecular aerogel of Example 1, CMpA2 is the natural macromolecular composite aerogel of Example 2, and CMpA5 is the natural macromolecular aerogel of Example 3. Detailed Implementation
[0038] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the invention. Furthermore, the technical features involved in the various embodiments of this invention described below can be combined with each other as long as they do not conflict with each other.
[0039] The first embodiment of the present invention provides a method for preparing porous materials with small molecule-mediated heterogeneous biomacromolecule interface recombination, comprising the following steps: (1) Mix at least two different biomacromolecules with a small molecule interface mediator to obtain a composite precursor; the small molecule interface mediator contains multiple action sites that can interact non-covalently with the at least two biomacromolecules respectively, so that the small molecule interface mediator interacts non-covalently with the biomacromolecules respectively to form a continuous recombinant heterogeneous interface. (2) After drying and structural fixation, the recombined heterogeneous interface forms a hierarchical porous network with interconnected channels, resulting in a porous material with small molecule-mediated heterogeneous biomacromolecule interface recombination.
[0040] This invention utilizes small molecules as non-covalent interface mediators, rather than just as ordinary functional additives or covalent crosslinking agents, to provide a controllable technical path for the interface adaptation and structural solidification of heterogeneous natural biomacromolecules.
[0041] In some embodiments, the non-covalent interaction is at least one of hydrogen bonding, polar interaction, electrostatic interaction, aromatic interaction, hydrophobic interaction, and van der Waals interaction.
[0042] In some embodiments, the biomacromolecules are selected from at least two of protein biomacromolecules, polysaccharide biomacromolecules, proteoglycans, and fungal mycelia.
[0043] Preferably, the protein-based biomolecules are selected from collagen, gelatin, silk fibroin, fibroin, elastin, or keratin; the polysaccharide-based biomolecules are selected from chitosan, chitin, cellulose, alginate, hyaluronic acid, starch, dextran, pectin, or agarose; and the fungal mycelium is a fungal mycelium containing a chitin and / or dextran fiber network. More preferably, the collagen is extracted from cowhide, pigskin, or sheepskin; More preferably, the fungal hyphae are selected from Ganoderma lucidum mycelium, oyster mushroom mycelium, shiitake mushroom mycelium, wood ear mushroom mycelium, lion's mane mushroom mycelium, enoki mushroom mycelium, or Turmeric corydalis mycelium.
[0044] In some embodiments, the small molecule interface mediator is selected from at least one of polyphenolic compounds, phenolic acid compounds, anthocyanin compounds, flavonoid compounds, and catechin compounds.
[0045] Preferably, the anthocyanin compounds are selected from grape skin anthocyanins, malvidin, petunia, paeoniflorin, delphinidin, or cyanidin; the phenolic acid compounds are selected from gallic acid, protocatechuic acid, caffeic acid, ferulic acid, or ellagic acid; and the catechin compounds are selected from catechin, epicatechin, or epigallocatechin.
[0046] Preferably, a system represented by collagen, Ganoderma lucidum mycelium, and grape skin anthocyanins is used to prepare a material with a porosity of approximately 96%–98%. This material exhibits significant inhibitory effects against Escherichia coli and Staphylococcus aureus, a hemolysis rate of less than 5%, and a low in vitro coagulation index after 30 seconds of contact with whole blood. Specifically, the biomolecules are collagen and Ganoderma lucidum mycelium, and the small-molecule interface mediator is grape skin anthocyanins. Grape skin anthocyanins contain phenolic hydroxyl groups, aromatic structures, and glycoside-related polar groups, which can interact with amide, hydroxyl, carboxyl, and aromatic groups in collagen, as well as chitin and dextran components in the cell wall of Ganoderma lucidum mycelium through hydrogen bonding, polar interactions, aromatic interactions, and van der Waals interactions. Through these multi-site non-covalent interactions, grape skin anthocyanins can regulate the interfacial contact and spatial distribution between collagen and mycelium, transforming the original local, discrete, or random heterogeneous contact into a more continuous and oriented interfacial network. The addition of Ganoderma lucidum mycelium mainly relies on the antibacterial and antioxidant properties of Ganoderma lucidum mycelium, and utilizes grape skin anthocyanins as a small molecule mediator to combine with collagen to prepare a porous material with antibacterial properties, high porosity, and high biocompatibility.
[0047] More preferably, the method for preparing porous materials with small molecule-mediated heterogeneous biomacromolecule interface recombination includes the following steps: (1) The collagen was swollen to obtain a collagen suspension. (2) Homogenize the fermented Ganoderma lucidum mycelium to obtain mycelium dispersion; mix the mycelium dispersion with collagen suspension, then add grape skin anthocyanins to obtain a composite liquid, pour it into a mold, freeze dry at low temperature, and then obtain natural macromolecular porous material.
[0048] More preferably, the mycelium fermentation time is 5-30 days.
[0049] More preferably, the concentration of the collagen suspension is 3 mg / mL to 10 mg / mL.
[0050] More preferably, the solvent for the collagen suspension is water, an aqueous acetic acid solution, or an aqueous sodium hydroxide solution.
[0051] More preferably, the concentration of grape skin anthocyanins in the collagen mixture is 0.5 mg / mL to 2 mg / mL.
[0052] More preferably, the concentration of Ganoderma lucidum mycelium solution is 0.5 mg / mL to 5 mg / mL.
[0053] More preferably, the mass ratio of Ganoderma lucidum mycelium in the Ganoderma lucidum mycelium solution, anthocyanins from grape skin, and collagen in the collagen mixture is 1:(0.3-1):(7-25).
[0054] More preferably, after adding Ganoderma lucidum mycelium liquid to the collagen mixture, glycerin is added to maintain a certain water content.
[0055] More preferably, the amount of glycerol added is 10%-20% of the total mass of Ganoderma lucidum mycelium in the Ganoderma lucidum mycelium solution and collagen in the collagen mixture.
[0056] A second embodiment of the present invention provides a porous material for preparing a small molecule-mediated heterogeneous biomacromolecule interface remodeling. This porous material exhibits high porosity, high biocompatibility, and a low in vitro coagulation index.
[0057] The third embodiment of the present invention provides the application of porous materials with small molecule-mediated heterogeneous biomacromolecule interface recombination as hemostatic materials.
[0058] The technical effects of the present invention will be further illustrated below with reference to embodiments and comparative examples.
[0059] Examples 1-6 and Comparative Examples 1-5 below used type I collagen as a protein-based biomacromolecule, Ganoderma lucidum mycelium as a biomacromolecule component containing a chitin and β-glucan fiber network, and grape skin anthocyanin extract as a small molecule interface mediator. Eight groups of materials were set up: C, M, CM, CpA, MpA, CMpA2, CMpA4, and CMpA5. C and M were used to characterize the basic structure of each individual biomacromolecule; CM was a heterogeneous biomacromolecule control without a small molecule interface mediator; CpA and MpA were used to characterize the structure and chemical environment after grape skin anthocyanin formed binary non-covalent contacts with collagen and mycelium, respectively; CMpA2, CMpA4, and CMpA5 were ternary examples with three different biomacromolecule ratios. The core comparison of the interface recombination technology is the comparison between CM and CMPA2, CMPA4, and CMPA5; C, M, CpA, and MpA are used to help distinguish single-component structures, binary interactions, and ternary interface recombination. Pleurotus ostreatus mycelium (Mp) and chitosan (CS) were selected as verification examples to prepare binary CMP (collagen-Pleurotus ostreatus mycelium) and CCS (collagen-chitosan), and ternary CMppA (collagen-Pleurotus ostreatus mycelium-anthocyanin) and CCSpA (collagen-chitosan-anthocyanin), respectively.
[0060] Example 1 S1. Weigh out the hydrous collagen extracted from bovine hide and dissolve it fully in 30 mL of ultrapure water to prepare a bovine hide collagen precursor solution with a concentration of 6 mg / mL, and store it at low temperature.
[0061] S2. Transfer the Ganoderma lucidum mycelium seeds in PDA solid medium to PDA liquid medium at a certain ratio and culture them. After the mycelium grows evenly, place it in a homogenizer to homogenize and prepare 10 mg / mL Ganoderma lucidum mycelium solution.
[0062] S3. Take 10.4 mL of Ganoderma lucidum mycelium with a concentration of 10 mg / mL from S2 and add it dropwise to the collagen precursor solution in S1; dissolve grape anthocyanins in water and mix them with bovine skin collagen at a solid content ratio of 1:10. After stirring evenly, add 10% glycerol of the solid mass of the collagen and Ganoderma lucidum mycelium mixture. Continue stirring for 3-5 minutes, let it stand for a period of time to self-assemble into a gel, and freeze-dry at low temperature to obtain a composite aerogel CmpA4 with high hemostatic ability.
[0063] Example 2 S1. Weigh out the hydrous collagen extracted from bovine hide and dissolve it fully in 30 mL of ultrapure water to prepare a collagen precursor solution with a concentration of 6 mg / mL. Store at low temperature.
[0064] S2. Transfer the Ganoderma lucidum mycelium seeds in PDA solid medium to PDA liquid medium at a certain ratio and culture them. After the mycelium grows evenly, place it in a homogenizer to homogenize and prepare 10 mg / mL Ganoderma lucidum mycelium solution.
[0065] S3. Take 5.6 mL of Ganoderma lucidum mycelium with a concentration of 10 mg / mL from S2 and add it dropwise to the collagen precursor solution in S1; dissolve grape anthocyanins in water and mix them evenly with collagen solids at a ratio of 1:10. After stirring evenly, add 10% glycerol by weight of the collagen and Ganoderma lucidum mycelium mixture and continue stirring for 3-5 minutes. Let it stand for a period of time to self-assemble into a gel, and freeze-dry it at low temperature to obtain a composite aerogel CMPA2 with high hemostatic ability.
[0066] Example 3 S1. Weigh out the hydrous collagen extracted from bovine hide and dissolve it fully in 30 mL of ultrapure water to prepare a collagen precursor solution with a concentration of 6 mg / mL. Store at low temperature.
[0067] S2. Transfer the Ganoderma lucidum mycelium seeds in PDA solid medium to PDA liquid medium at a certain ratio and culture them. After the mycelium grows evenly, place it in a homogenizer to homogenize and prepare 10 mg / mL Ganoderma lucidum mycelium solution.
[0068] S3. Take 20 mL of Ganoderma lucidum mycelium with a concentration of 10 mg / mL from S2 and add it dropwise to the collagen precursor solution in S1. Dissolve grape anthocyanins in water and mix them with collagen solids at a ratio of 1:10. After stirring evenly, add 10% glycerol by weight of the collagen and Ganoderma lucidum mycelium mixture. Continue stirring for 3-5 minutes, let it stand for a period of time to self-assemble into a gel, and freeze-dry at low temperature to obtain a composite aerogel CMPA5 with high hemostatic ability.
[0069] Comparative Example 1 Except for the absence of mycelium and grape skin anthocyanins, a porous collagen material was prepared by accurately weighing bovine hide-extracted hydrous collagen and dissolving it fully in 30 mL of ultrapure water to prepare a collagen precursor solution with a concentration of 6 mg / mL. After fixing the structure and drying, the resulting material was material C.
[0070] Comparative Example 2 Ganoderma lucidum mycelial seeds in PDA solid medium were transferred to PDA liquid medium at a certain ratio and cultured until the mycelia grew uniformly. The mycelia were then homogenized in a homogenizer to prepare a 10 mg / mL Ganoderma lucidum mycelial solution. 40 ml of this solution was taken, structurally fixed, and dried; this solution is denoted as material M.
[0071] Comparative Example 3 Weigh out the hydrous collagen extracted from bovine hide and dissolve it fully in 30 mL of ultrapure water to prepare a collagen precursor solution with a concentration of 6 mg / mL. Add the precursor solution dropwise to 10.4 mL of homogenized mycelial solution with a concentration of 10 mg / mL to prepare a collagen-mycelial binary material, denoted as material CM.
[0072] Comparative Example 4 Weigh out the hydrous collagen extracted from bovine hide and dissolve it fully in 30 mL of ultrapure water to prepare a collagen precursor solution with a concentration of 6 mg / mL. Dissolve grape skin anthocyanins in water and mix them evenly with the collagen solids at a ratio of 1:10 to prepare a collagen-grape skin anthocyanin binary material, denoted as material CpA.
[0073] Comparative Example 5 Ganoderma lucidum mycelial seeds in PDA solid medium were transferred to PDA liquid medium at a certain ratio and cultured until the mycelia grew uniformly. The mycelia were then homogenized in a homogenizer to prepare a 10 mg / mL Ganoderma lucidum mycelial solution. 40 ml of grape skin anthocyanins were dissolved in water and mixed uniformly with the mycelial solids at a ratio of 1:20. The mixture was then fixed in structure and dried to prepare a mycelium-grape skin anthocyanin binary material, denoted as MpA.
[0074] Example 4 S1. Weigh out the hydrous collagen extracted from bovine hide and dissolve it fully in 30 mL of ultrapure water to prepare a collagen precursor solution with a concentration of 6 mg / mL. Store at low temperature.
[0075] S2. Pleurotus ostreatus seeds in PDA solid medium are transferred to PDA liquid medium at a certain ratio and cultured. When the mycelium grows evenly, it is homogenized in a homogenizer to prepare 10 mg / mL oyster mushroom mycelium solution.
[0076] S3. Take 20 mL of the 10 mg / mL *Pleurotus ostreatus* mycelium from S2 and add it dropwise to the collagen precursor solution in S1. Dissolve grape anthocyanins in water and mix them evenly with the collagen solids at a ratio of 1:10. After stirring evenly, add 10% glycerol (based on the solid mass of the collagen and *Ganoderma lucidum* mycelium mixture) dropwise. Continue stirring for 3-5 minutes, allow it to stand for a period of time to self-assemble into a gel, and freeze-dry at low temperature to obtain a composite aerogel CM with highly efficient hemostatic ability. p pA.
[0077] S4. Take 20 mL of the 10 mg / mL *Pleurotus ostreatus* mycelium from S2 and add it dropwise to the collagen precursor solution in S1. After stirring evenly, add 10% (by weight of the solids in the collagen and *Ganoderma lucidum* mycelium mixture) of glycerol to prepare the composite aerogel CM. p .
[0078] Example 5 S1. Weigh out the hydrous collagen extracted from bovine hide and dissolve it fully in 30 mL of ultrapure water to prepare a collagen precursor solution with a concentration of 6 mg / mL. Store at low temperature.
[0079] S2. Dissolve chitosan in an acetic acid solution of a certain concentration to prepare a chitosan solution of 20 mg / ml.
[0080] S3. Take 2 mL of the 20 mg / mL chitosan solution from S2 and add it dropwise to the collagen precursor solution in S1. Dissolve grape anthocyanins in water and mix them with collagen protein at a mass ratio of 1:10. After stirring evenly, add 10% glycerol by weight of the solids of the collagen and chitosan mixture. Continue stirring for 3-5 minutes. Let it stand for a period of time to self-assemble into a gel. Freeze-dry at low temperature to obtain a composite aerogel CCSpeA with high hemostatic ability.
[0081] S4. Take 2 mL of the 20 mg / mL chitosan solution from S2 and add it dropwise to the collagen precursor solution in S1. After stirring evenly, add 10% glycerol (based on the solid mass of the collagen and Ganoderma lucidum mycelium mixture) to prepare composite aerogel CCS.
[0082] Example 6 S1. Weigh out the hydrous collagen extracted from bovine hide and dissolve it fully in 30 mL of ultrapure water to prepare a bovine hide collagen precursor solution with a concentration of 6 mg / mL, and store it at low temperature.
[0083] S2. Transfer the Ganoderma lucidum mycelium seeds in PDA solid medium to PDA liquid medium at a certain ratio and culture them. After the mycelium grows evenly, place it in a homogenizer to homogenize and prepare 10 mg / mL Ganoderma lucidum mycelium solution.
[0084] S3. Take 10.4 mL of Ganoderma lucidum mycelium with a concentration of 10 mg / mL from S2 and add it dropwise to the collagen precursor solution in S1. Mix gallic acid, catechin, and protocatechin with bovine collagen extract at a ratio of 1:10. After stirring evenly, add 10% glycerol (based on the solid mass of the collagen and Ganoderma lucidum mycelium mixture) and stir continuously for 3-5 minutes. Let it stand for a period of time to self-assemble into a gel. Freeze-dry at low temperature to obtain composite aerogels CMGA (collagen-mycelium-gallic acid), CMCA (collagen-mycelium-catechin), and CMPCA (collagen-mycelium-protocatechin) with high hemostatic ability.
[0085] Results and Analysis: like Figure 1 As shown, the composite aerogel (CM) with added Ganoderma lucidum mycelium in Comparative Example 3 and the binary aerogel CpA combining collagen and grape skin pigment in Comparative Example 4 form a more pronounced porous structure compared to the pure collagen aerogel (C) in Comparative Example 1. The pure mycelium aerogel (M) in Comparative Example 2 also exhibits an irregular porous structure. In Comparative Example 5, the binary aerogel MpA formed by the combination of grape skin pigment mycelium exhibits a disordered porous structure. However, the ternary aerogels CMpA2, CMpA4, and CMpA5, which introduced small molecules of grape skin pigment in Examples 1-3, all exhibit a dense and ordered layered porous interpenetrating structure. This small molecule-regulated interpenetrating behavior of the composite aerogel was further characterized by fluorescence confocal microscopy. Figure 2 Compared with the collagen-mycelium binary material CM, CMPA2, CMPA4, and CMPA5, after the addition of grape skin anthocyanins, formed more continuous pore walls and layered porous structures, with different ratios of the system exhibiting different degrees of structural reorganization.
[0086] Figure 2 The fluorescence confocal results further indicate that the distribution of collagen and mycelium in the ternary material is more uniform, and the degree of contact and interpenetration between the two is improved.
[0087] like Figure 3 As shown, the orientation parameters and SAXS scattering diagrams indicate that the addition of grape skin anthocyanins alters the orientation state and structural anisotropy of the material, suggesting that the small molecule-mediated effect not only changes the micropore wall morphology of the material but also regulates the spatial organization of the internal structural units.
[0088] like Figure 4As shown, the peak positions and peak area ratios of C 1s, N 1s, and O 1s in the CMPA system changed compared to the single-component and binary systems, indicating that the chemical environment of collagen, mycelium, and anthocyanin-related functional groups changed after the addition of small molecules.
[0089] like Figure 5 As shown, Examples 4 and 5 investigated this interface-mediated principle in the collagen-chitosan system and another system containing hyphae. The introduction of pA promoted the consolidation of the pore walls, enhanced the anisotropy of SAXS, and improved the tensile strength, indicating that the observed structural reorganization was not a random phenomenon under a single CMPA composition.
[0090] Figure 6 As shown in Example 6, a small molecule mediator screening study revealed that different phenolic mediators, including catechin (CA), gallic acid (GA), and p-hydroxybenzoic acid (PCA), produced different morphologies, SAXS responses, and mechanical properties. This result indicates that the strategy is chemoselective, depending on the compatibility between the mediator's chemical properties and the C–M heterointerface, rather than a universal outcome of any small phenolic molecule addition. Figure 7 As shown, the surface potential results further indicate that CMpA2, CMpA4, and CMpA5 form interfacial charge states different from C, M, CM, CpA, and MpA, suggesting that the ternary recombination process is accompanied by a readjustment of surface functional groups and charge distribution.
[0091] Figure 8 As shown, different components exhibit specific structural responses to pA. In Comparative Example 4, the CpA (collagen-plant-derived anthocyanin) composite material enhances the porosity of the layered structure by densifying the pore walls; while in Comparative Example 5, MpA refines the dense layered structure into a finer porous network. This dual regulation promotes hyphae-dependent structural evolution within the ternary system, from the fragmented recombinant regions in Example 2 CMpA2 to the more continuous mesoscale layered frameworks in Example 2 CMpA4 and Example 3 CMpA5. This progressive evolution improves the integrity of the interpenetrating network and enhances the spatial synergy between collagen-rich and hyphae-derived regions. These changes indicate a gradual increase in mesoscale orientation consistency, consistent with the trend of densification of the layered structure and reduction in porosity relative to CM.
[0092] comprehensive Figures 1-8 It is known that grape skin anthocyanins do not exist merely as ordinary functional additives, but rather participate in the regulation of the heterogeneous interface between collagen and mycelium through multi-site non-covalent interactions, causing synergistic changes in the material's pore wall continuity, component distribution, structural orientation, functional group chemical environment, and surface charge state, thereby forming a small molecule-mediated recombinant heterogeneous interface.
[0093] The antibacterial properties of Examples 1-3 and Comparative Examples 1-5 were characterized and analyzed. For example... Figures 9-12 The inhibitory effects on Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli were studied separately. The results showed that the composite aerogels all had high antibacterial rates, exceeding 99% in Examples 1-3. Regarding the inhibitory effect on Staphylococcus aureus, Comparative Example 1 (collagen aerogel) showed no significant inhibitory effect, while Comparative Example 3 (with added hyphae (CM),) Comparative Example 4 (grape skin anthocyanin (CpA),) and the film (CMpA) added in Examples 1-3, and Comparative Example 5 (hyphae and grape skin pigment (MpA)) all showed significant inhibitory effects on Escherichia coli. Further characterization of the cell morphology of Escherichia coli and Staphylococcus aureus was conducted. Figure 11 , Figure 12 This demonstrates the inhibitory effect on both Gram-positive and Gram-negative bacteria, showing that the bacteria inhibit growth by damaging the surface of the bacterial cells, thus achieving a bacteriostatic effect.
[0094] Further characterization of the biocompatibility and hemostatic properties of the aerogel (e.g.) Figures 13-15 ).like Figure 13 The rabbit blood absorption capacity was assessed, showing that pure collagen (C) in Comparative Example 1 was ineffective in retaining blood, and the blood easily diffused into the surrounding tissues. However, Comparative Examples 2 (M), 3 (CM), and the CMpA4, CMpA2, and CMpA5 systems in Examples 1-3 all exhibited significantly enhanced blood permeability and retention capacity, with the ternary system showing particularly significant enhancement. This indicates that the ordered porous network constructed by the mycelium provides the structural basis for rapid blood adsorption and spatial confinement. Blood compatibility was systematically evaluated using in vitro hemolysis experiments. Figure 14 Physiological saline and deionized water were used as negative and positive controls, respectively. Quantitative results showed that the hemolysis rate of Comparative Example 1 (C) group was 8.53%, significantly higher than that of Comparative Example 2 (M), Comparative Example 3 (CM), and the CMpA group in Examples 1-3 (0.74%). However, all samples were far below the 5% safety threshold for biomedical materials, indicating that the ternary network synergistically constructed by mycelium and pA significantly improved blood compatibility. To systematically evaluate the procoagulant ability, the blood coagulation index (BCI) was measured after incubation with whole blood for 30 s, 1 min, and 5 min. Figure 15 and Figure 16The supernatant in the blank group remained bright red throughout, indicating that a large number of red blood cells had not coagulated. Comparative Example 1 (C group) showed significant fading after 5 minutes. The M group exhibited some procoagulant ability. In contrast, Comparative Example 3 (CM) and the CMPA group in Examples 1-3 showed nearly colorless supernatants within 30 seconds. The BCI quantification results were completely consistent with these findings. At all time points, CMPA in Examples 1-3 showed the lowest BCI values, significantly superior to Comparative Example 1 (C), Comparative Example 2 (M), and Comparative Example 3 (CM). Meanwhile, Comparative Example 4 (CpA), Comparative Example 5 (MpA), and the ternary system (CMpA4) with different ratios in Examples 1-3 also exhibited excellent procoagulant ability within the 30-5 minute range. Considering the blood absorption behavior, hemolytic safety, and BCI results, it can be concluded that the ordered porous interpenetrating network mediated by grape skin pigments not only significantly improved the blood compatibility of the material but also achieved rapid hemostasis through a synergistic mechanism of efficient capillary adsorption, cell enrichment, and interface-promoted coagulation. These results establish CMPA ternary aerogel as a suitable material for constructing hemostatic porous materials, exhibiting rapid blood absorption, low hemolysis rate, and low BCI in the tested formulations.
[0095] Those skilled in the art will readily understand that the above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.
Claims
1. A method for preparing porous materials with small molecule-mediated heterogeneous biomacromolecule interface recombination, characterized in that, Includes the following steps: (1) Mix at least two different biomacromolecules with a small molecule interface mediator to obtain a composite precursor; the small molecule interface mediator contains multiple action sites that can interact non-covalently with the at least two biomacromolecules respectively, so that the small molecule interface mediator interacts non-covalently with the biomacromolecules respectively to form a continuous recombinant heterogeneous interface. (2) After drying and structural fixation, the recombined heterogeneous interface forms a hierarchical porous network with interconnected channels, resulting in a porous material with small molecule-mediated heterogeneous biomacromolecule interface recombination.
2. The method for preparing porous materials with small molecule-mediated heterogeneous biomacromolecule interface recombination as described in claim 1, characterized in that, The non-covalent interaction is at least one of hydrogen bonding, polar interaction, electrostatic interaction, aromatic interaction, hydrophobic interaction, and van der Waals interaction.
3. The method for preparing porous materials with small molecule-mediated heterogeneous biomacromolecule interface recombination as described in claim 1, characterized in that, The biomacromolecules are selected from at least two of the following: protein biomacromolecules, polysaccharide biomacromolecules, proteoglycans, and fungal mycelia.
4. The method for preparing porous materials with small molecule-mediated heterogeneous biomacromolecule interface recombination as described in claim 3, characterized in that, The protein-based biomolecules are selected from collagen, gelatin, silk fibroin, fibroin, elastin, or keratin; the polysaccharide-based biomolecules are selected from chitosan, chitin, cellulose, alginate, hyaluronic acid, starch, dextran, pectin, or agarose; the fungal mycelium is a fungal mycelium containing a chitin and / or dextran fiber network. Preferably, the fungal hyphae are selected from Ganoderma lucidum mycelium, oyster mushroom mycelium, shiitake mushroom mycelium, wood ear mushroom mycelium, lion's mane mushroom mycelium, enoki mushroom mycelium, or Turmeric corydalis mycelium.
5. The method for preparing porous materials with small molecule-mediated heterogeneous biomacromolecule interface recombination as described in claim 1, characterized in that, The small molecule interface mediator is selected from at least one of polyphenolic compounds, phenolic acid compounds, anthocyanin compounds, flavonoid compounds, and catechin compounds.
6. The method for preparing porous materials with small molecule-mediated heterogeneous biomacromolecule interface recombination as described in claim 5, characterized in that, The anthocyanin compounds are selected from grape skin anthocyanins, malvidin, petunia extract, paeoniflorin, delphinidin, or cyanidin. The phenolic acid compounds are selected from gallic acid, protocatechuic acid, caffeic acid, ferulic acid, or ellagic acid; The catechin compounds are selected from catechins, epicatechins, or epigallocatechins.
7. The method for preparing porous materials with small molecule-mediated heterogeneous biomacromolecule interface recombination as described in claim 1, characterized in that, The drying process is either freeze-drying or supercritical drying.
8. Porous materials prepared by any one of claims 1-7, characterized by small molecule-mediated heterogeneous biomacromolecule interface recombination.
9. The application of the porous material described in claim 8, which mediates the recombination of heterogeneous biological macromolecule interfaces, in the preparation of hemostatic materials.
10. The application as described in claim 9, characterized in that, The hemostatic material is either a wound compression hemostatic material or a cavity filling hemostatic material.
